Aarti Drugs posts steady FY26 growth & sharp Q4 rebound despite margin pressure

KIMS Hospitals posts strong revenue growth but profits slip sharply in FY26

Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26

Cupid shatters FY26 guidance with record 93% revenue jump & 165% profit surge

Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels

Alivus Life Sciences posts steady FY26 growth as margins surge past guidance

The company reported free cash flow of Rs. 2,590 Mn for FY26

Bayer’s NUBEQA combo shows 71% drop in risk of progression or death in prostate cancer trial

Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm

FDA expands Enhertu use in early HER2-positive breast cancer

AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease

Lupin debuts in Dow Jones best-in-class indices for ESG performance

The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index

Medix Biochemica unleashes $5 million expansion to secure future of IVD supply chain

The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030

Merck reports breakthrough Phase 3 win for sac-TMT in endometrial cancer

Teva study exposes major diagnosis gap in Tardive Dyskinesia

According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD